Vis enkel innførsel

dc.contributor.authorNome, Marianne Eikhom
dc.contributor.authorEuceda, Leslie R.
dc.contributor.authorJabeen, Shakila
dc.contributor.authorDebik, Julia
dc.contributor.authorBathen, Tone Frost
dc.contributor.authorGiskeødegård, Guro F.
dc.contributor.authorTasken, Kristin Austlid
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorHalvorsen, Bente
dc.contributor.authorYndestad, Arne
dc.contributor.authorBorgen, Elin
dc.contributor.authorGarred, Øystein
dc.contributor.authorAukrust, Pål
dc.contributor.authorUeland, Thor
dc.contributor.authorEngebraaten, Olav
dc.contributor.authorKristensen, Vessela N.
dc.contributor.authorTekpli, Xavier
dc.identifier.citationInternational Journal of Cancer. 2019, 146 223-235.nb_NO
dc.description.abstractAngiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti‐vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. At four time points during neoadjuvant chemotherapy ± bevacizumab of receptor tyrosine‐protein kinase erbB‐2‐negative breast cancers, we measured metabolites and inflammation‐related markers in patient's serum. We report significant changes in the levels of several molecules induced by bevacizumab, the most prominent being an increase in pentraxin 3 (PTX3) and von Willebrand factor (VWF). Serum levels of AXL, VWF and pulmonary and activation‐regulated cytokine (PARC/CCL18) reflected response to chemotherapy alone or in combination with bevacizumab. We further analyzed serum cytokines in relation to tumor characteristics such as gene expression, tumor metabolites and tumor infiltrating leukocytes. We found that VWF and growth‐differentiation factor 15 tumor mRNA levels correlated with their respective serum protein levels suggesting that these cytokines may be produced by tumors and outflow to the bloodstream while influencing the tumor microenvironment locally. Finally, we used binomial logistic regression which allowed to predict patient's response using only 10 noninvasive biomarkers. Our study highlights the potential of monitoring circulating levels of cytokines and metabolites during breast cancer therapynb_NO
dc.publisherJohn Wiley & Sons Ltd on behalf of UICCnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleSerum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancersnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.journalInternational Journal of Cancernb_NO
dc.description.localcode© 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.nb_NO
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal